FDA updates Repros on Proellex clinical hold
This article was originally published in Scrip
Executive Summary
The US FDA has provided Repros Therapeutics with further clarification over the full clinical hold status of its lead drug, the orally selective progesterone antagonist Proellex, and guidance for the company to get the hold lifted. The drug was being looked at for the treatment of chronic symptomatic uterine fibroids and associated anaemia, as well as endometriosis.